AURORA SPINE ANNOUNCES ATTENDANCE AT NORTH AMERICAN NEUROMODULATION SOCIETY (NANS) ANNUAL MEETING
18 Janeiro 2024 - 9:21AM
Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:
ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative
medical devices that improve spinal surgery outcomes, today
announced that it will be participating in the North American
Neuromodulation Society (“NANS”) Annual Meeting from January 18-21
in Las Vegas, Nevada. The NANS Annual Meeting is a prominent
medical conference that brings together healthcare professionals,
researchers, and experts in the field of neuromodulation.
Aurora will be showcasing two Sacroiliac Joint
(SI Joint) fusion products. Silo TFX and Silo offer physicians
options to stabilize the SI Joint, helping patients with access to
treatment for their SI joint dysfunction.
Aurora Spine will be presenting data from the
recent publication of the first 6-month clinical evaluation from
the REFINE Screwless™ ZIP™ Study of its ZIP Interspinous Fixation
device in the Journal of Pain Research.
About Aurora Spine
Aurora Spine is focused on bringing new solutions
to the spinal implant market through a series of innovative,
minimally invasive, regenerative spinal implant technologies.
Additional information can be accessed at www.aurora-spine.com or
www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking
information that involves substantial known and unknown risks and
uncertainties, most of which are beyond the control of Aurora
Spine, including, without limitation, those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking
Information" in Aurora Spine's final prospectus (collectively,
"forward-looking information"). Forward-looking information in this
news release includes information concerning the proposed use and
success of the company’s products in surgical procedures. Aurora
Spine cautions investors of Aurora Spine's securities about
important factors that could cause Aurora Spine's actual results to
differ materially from those projected in any forward-looking
statements included in this news release. Any statements that
express, or involve discussions as to, expectations, beliefs,
plans, objectives, assumptions or future events or performance are
not historical facts and may be forward-looking and may involve
estimates, assumptions and uncertainties which could cause actual
results or outcomes to differ unilaterally from those expressed in
such forward-looking statements. No assurance can be given that the
expectations set out herein will prove to be correct and,
accordingly, prospective investors should not place undue reliance
on these forward-looking statements. These statements speak only as
of the date of this press release and Aurora Spine does not assume
any obligation to update or revise them to reflect new events or
circumstances.
For more information, please contact:
Aurora Spine Corporation
Trent Northcutt President and Chief Executive
Officer (760) 424-2004
Chad Clouse Chief Financial Officer (760)
424-2004
www.aurora-spine.com
Aurora Spine (TSXV:ASG)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Aurora Spine (TSXV:ASG)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025